Figure S1 from Everolimus Inhibits the Progression of Ductal Carcinoma In Situ to Invasive Breast Cancer Via Downregulation of MMP9 Expression

Autor: Lu-Zhe Sun, Ismail Jatoi, Virginia Kaklamani, Andrew J. Brenner, Alia Nazarullah, Larry E. Broome, Guixi Zheng, Bingzhi Wang, Hakim Bouamar, Kyle Pressley, Xiao-Fei Ding, Guang Chen
Rok vydání: 2023
DOI: 10.1158/1078-0432.22479284
Popis: mTOR inhibition decreases MMP9 expression. A, Everolimus treatment for 24 hours did not reduced MMP2 protein levels in SUM225 cells. B, C and D figures were the MMP-9 IHC quantification data measuring average optical density using ImageJ d 1.47 software. B, one-week Everolimus treatments at 2 mg/kg/day significantly decreased MMP9 protein levels in the mammary gland of MMTV/neu mice (n=3). C, one-week-Everolimus treatments at 2 mg/kg decreased MMP9 protein levels in the mammary gland of SUM225-MIND mouse mammary tissues detected by IHC (n=4). D, one-week-rapamycin treatments at 2 mg/day reduced MMP9 protein levels in mammary glands of DCIS patients detected by IHC. **p
Databáze: OpenAIRE